Business
Update on AI/ML-Ab service offering
Update on AI/ML-Ab service offering.
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n\nFusion Antibodies plc\n(\"Fusion\" or the \"Company\")\n \nUpdate on AI/ML-AbTM service offering\n \nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has received a first purchase order for its AI/ML-AbTM (pronounced AIM-Lab) services. The customer, based in Australia, was introduced under the framework of the agreement the Company has recently entered into with a leading US-based AI/ML (artificial intelligence and machine learning) company, and the details of this were announced on 21 August 2023. This purchase order demonstrates commercial traction for AI/ML-AbTM and the Directors believe that there is significant market potential for this service offering.\n \nFusion Antibodies CEO, Adrian Kinkaid said: \"We are delighted to be able to announce the first order for our AI/ML-AbTM service offering. This confirms that we are pursuing the right strategy at Fusion and that the market values the services we offer. As our industry rapidly evolves to find new ways to hasten the discovery of better bio-therapeutics to take to the clinic, Fusion is well positioned at the forefront of Antibody discovery and development processes, including those using AI/ML, and with all the resources required to meet the growing need for our services.\"\n \nEnquiries: \n \n\n\n\nFusion Antibodies plc\n\n\nwww.fusionantibodies.com\n\n\n\n\nAdrian Kinkaid, Chief Executive Officer\nRichard Buick, Chief Scientific Officer\n\n\nVia Walbrook PR\n\n\n\n\n\n\n\n \n\n\n\n\nAllenby Capital Limited\n\n\nTel: +44 (0)20 3328 5656 \n\n\n\n\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nAnna Dunphy\n\n\nMob: +44 (0)7876 741 001\n\n\n\n\n\n\n\n\n \nAbout Fusion Antibodies plc\n \nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\n \nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of serv...